The origin and significance of blood hyperviscosity in subjects with acute stroke has been controversial. It has been argued that viscous abnormalities simply reflect either elevated hematocnt or an acute-phase response to the stroke itself. To address these issues, we measured the factors that determine blood viscosity in a cross-sectional study of 430 subjects, including 135 with acute stroke, 89 with acute transient ischemic attacks of the brain, 115 with recognized risk factors for stroke, and 91 healthy controls. The at-risk group was balanced with the acute stroke group for types of risk factors and medication usage, and all four groups were balanced for age. The viscosity of whole blood at low rates of shear and the plasma viscosity were significantly elevated in both groups with cerebrovascular symptoms and in the at-risk group compared with the healthy controls. The severity of hyperviscosity was stroke group > transient ischemic attack group > at-risk group > healthy controls. Increased viscosity of whole blood was associated with an elevated plasma fibrinogen concentration and with a decreased albumin/ globulin ratio. This study provides evidence that blood hyperviscosity is present not only in subjects with acute brain infarction, but also in those with risk factors for stroke, and that these abnormalities are, to a considerable degree, chronic (Stroke 1991^2:162-168)
W
hether elevated blood viscosity in subjects suffering acute stroke is causally related to the ischemic event or simply reflects the presence of secondary acute-phase reactants remains controversial. An etiologic role for blood hyperviscosity in stroke is supported by reports that blood viscosity is elevated in patients with recognized stroke risk factors including diabetes mellitus, ischemic heart disease, and tobacco use. 1 -3 Furthermore, elevations in either of two influential components of whole-blood viscosity, hematocrit or fibrinogen concentration, are associated with an increased risk for stroke. 4 -6 Despite the identification of viscous abnormalities in patients with either symptomatic cerebrovascular disease or related risk factors, an evaluation of the severity of viscous abnormalities and the factors that contribute to them among these groups has not been conducted. We recently completed a comprehensive cross-sectional study of blood viscosity in subjects with acute ischemic stroke or transient ischemic attack of the brain (TIA) and in subjects with recognized risk factors for stroke, together with an age-balanced group of healthy controls. In each group we identified the factors that accounted for plasma and whole-blood viscosity.
Subjects and Methods
Subjects were recruited from the wards and outpatient clinics of the Portland Veterans Administration Hospital and the Oregon Health Sciences University into four groups: patients with stroke (group I), those with TIA (group II), those with stroke risk factors (group III), and normal subjects balanced for age with the stroke group (group IV). Subjects were eligible for recruitment into group I if they had experienced an ischemic stroke within the past 7 days. Subjects with hemorrhagic stroke or subarachnoid hemorrhage were excluded. Diagnosis of the probable stroke mechanism was based on criteria used by the Stroke Data Bank. 7 Group II consisted of subjects who had experienced a TIA within the past 14 days. Exclusion criteria included symptoms associated with seizures, brain tumors, or subdural hematomas; syncope or vertigo without focal brain stem symptoms or signs; nonspecific dizziness; and symptoms associated with drug or alcohol intoxication. Group III consisted of patients with risk factors for stroke that have been identified in previous epidemiological studies (e.g., hypertension, diabetes mellitus, cardiovascular disease, smoking habit, or known cerebrovascular atherosclerosis). 8 Patients with a history of stroke or TIA were eligible for inclusion in group III provided they had been asymptomatic for a minimum of 6 months prior to enrollment. Volunteers comprising group IV denied the presence of risk factors for stroke, were currently nonsmoking, were not taking prescription medication, and were enrolled only if results of their complete blood count (CBC) and serum chemistry screen were within the normal range. Patients with vasculitis, cancer, or severe debilitating systemic illness were excluded from all groups. Subjects were classified as exsmokers only if they had abstained from smoking for at least 6 months prior to enrollment. Enrollment was continuously monitored to balance the groups for age and sex and to match the number and types of risk factors in group III with those in group I. Medications received at the onset of stroke or TIA and drugs being administered at the time of viscosity testing were recorded.
All subjects gave written informed consent to participate and undergo phlebotomy by members of the neurology staff. Nonfasting blood samples were drawn, usually between 8 and 11 AM, from an antecubital vein by venipuncture with minimal stasis. Samples were anticoagulated with either the disodium salt of ethylenediaminetetraacetic acid for CBC and whole-blood and plasma viscosity determinations or diluted 9:1 (vol:vol) in a solution of 3.8% sodium citrate for fibrinogen concentration measurement. Samples were also collected without anticoagulant for serum chemistry and serum viscosity determinations.
Measurements performed by laboratories of the Clinical Pathology Department of the Oregon Health Sciences University included CBC (SIV Plus, Coulter Corp., Hialeah, Fla.), serum chemistries (737 analyzer, Hitachi, Scientific Instruments, Mountain View, Calif.), fibrinogen concentration, and modified thrombin clotting time using Dade reagents (AHS del Caribe, Inc., Aguada, Puerto Rico). For further analysis of the blood protein profile, both globulin concentration and the albumin: globulin (A/G) ratio were calculated from the total protein and albumin values as globulin=total protein concentration minus albumin concentration and A/G ratio=albumin concentration divided by globulin concentration. In the context of this report, globulin refers to proteins such as a 2 -macroglobulins and orosomucoid in addition to the traditional immunoglobulins. Whole-blood and plasma viscosity were measured as described previously. 9 The apparent viscosity of whole blood was measured ^ 1 hour after venipuncture at 25°C without hematocrit adjustment at low (0.145 and 5.76 sec" 1 ) and intermediate (124 sec" 1 ) rates of shear using a Contraves LS2 rotational viscometer (Con- traves, AG, Zurich). Plasma and serum viscosity were measured at 25°C by Ostwald viscometry in a microviscometer (Cannon Instrument Co., State College, Pa.).
Summary statistics (mean and standard deviation) were calculated for each continuous variable, whereas frequency variables were summarized by expressing the data as percentages. When analysis of variance indicated a significant (/><0.05) difference among groups, the Bonferroni correction for multiple comparisons was applied to post-hoc t tests to assess the significance of differences between groups. The significance of differences between groups was assessed with Student's t test, and associations among hematologic and plasma and serum protein variables were assessed with Pearson's correlation coefficient.
Stepwise multiple regression analysis using SAS 10 was employed to determine the predictors of both wholeblood and plasma viscosity. Stepwise discriminant analysis with BMDP-7M, U followed by Tukey's jackknife procedure, was used to identify the set of viscosity-related variables best distinguishing subjects with acute stroke from those with epidemiological risk factors for stroke. The jackknife procedure is a resampling technique that measures the degree to which the results depend on the particular data points selected for analysis.
Results
As shown in Table 1 , a total of 430 subjects were enrolled. For group I the mean±SD interval between the onset of stroke and the measurement of viscosity and clinical laboratory parameters was 4.4±3.5 days; for group II the interval after TIA was 5.6±7.9 days. Men comprised the majority of subjects in all groups, although the proportion of women was slightly higher in group IV. The overall population was largely (>95%) Caucasian and was drawn from a wide spectrum of socioeconomic and occupational backgrounds. The groups were well balanced for age, with 90% of all subjects aged ^50 years. The median number of risk factors was two in group I, two and a half in group II, and two in group HI, with >25% of the subjects in these three groups having three or more recognized risk factors for stroke. For groups I, II, and III the most prevalent risk factors were hypertension and heart disease, with almost 40% of the subjects having both risk factors and fully 82% having either one or both. Atheroembolism was the probable mechanism for cerebrovascular symptoms in 54% of the subjects in group I and 68% of those in group II. Cardioembolism accounted for 12% of the symptoms in both groups I and II. Lacunar infarction was present in 25% of the group I subjects but in only 3% of the group II subjects. Computed brain tomography or magnetic resonance imaging of the brain was obtained for 98% of the subjects in group I, 93% in group II, and 43% in group III. Of the subjects scanned, 88% in group I and 60% in group II had abnormalities consistent with the cerebrovascular diagnosis. In group III 30% of the scans were abnormal, agreeing well with a clinical history of stroke or TIA in 42% of this group and prior carotid endarterectomy in 20%.
The patterns of medication usage by subjects in groups I, II, and III were similar. Aspirin and related antiaggregatory drugs were being taken by 69% of the subjects in group I, 87% in group II, and 59% in group III, as well as by 25% of those in group IV. Nearly all subjects in groups I and II and 85% in group III were receiving either antiaggregatory or anticoagulant drugs at the time of blood sampling. Table 2 lists the mean±SD hematologic, plasma and serum protein, and viscometric determinations for each group. Results are presented for diagnostic groups (i.e., stroke and TIA) because no differences in viscosity-related variables were found for infarcts Candidates for entry included all hematologic and biochemical laboratory variables and plasma and serum viscosity. I, patients with acute ischemic stroke; II, those with transient ischemic attack of brain; III, those with risk factors for stroke; IV, normal subjects; A/G, albumin concentration-to-globulin concentration.
arising from differing mechanisms. These variables are related since both the cellular and plasmatic component are responsible for the viscosity of whole blood. Hematocrit in groups I and II did not differ from those in groups III and IV. The mean erythrocyte hemoglobin concentration, however, was lower (p<0.05) in group I than in group IV. Groups I, II, and III had significantly higher leukocyte counts (WBC) than group IV. Fibrinogen concentration was significantly higher in group I than in groups III and IV. Conversely, the albumin concentration and the A/G ratio were significantly lower in groups I and II than in group IV. Plasma viscosity and whole-blood viscosity measured at low shear rates were likewise significantly greater in groups I, II, and III than in group IV. Although measured in only 20% of the subjects, serum viscosity in group I was significantly higher than that in group IV (p<0.05).
Stepwise multiple regression analysis was used to determine the predictors of apparent whole-blood viscosity shown in Table 3 . Candidates for entry into the model included all hematologic and biochemical laboratory values as well as plasma and serum viscosity. The primary determinants of whole-blood viscosity were hematocrit and plasma viscosity. Additional variables, including the fibrinogen and calculated globulin concentrations, the A/G ratio, the nonfasting blood glucose level, and WBC, are also related to apparent whole-blood viscosity. Moreover, the A/G ratio was the only variable significantly (/?<0.001) correlated with all of the above viscosity-related variables. The overall correlation coefficients for the A/G ratio were -0.44, 0.61, -0.57, -0.23, -0.84, -0.33, and -0.19 with fibrinogen concentration, albumin concentration, plasma viscosity, WBC, globulin concentration, whole-blood viscosity, and glucose concentration, respectively. The lowest A/G ratios were observed in those group I patients who had a history of stroke or TIA (1.42 ±0.30, n=ll, /><0.06 compared with group I patients with no history of cerebrovascular events, 1.53±0.34, n=52). As shown in Table 3 , these relations are generally the same for groups I, III, and IV.
The plasma protein profile strongly influences plasma viscosity, as shown in Table 4 . The calculated concentration of globulin and the concentration of fibrinogen were the primary predictors of plasma viscosity, with contributions by the total protein level, the A/G ratio, and to a lesser extent the nonfasting glucose and cholesterol concentrations.
Since hyperviscosity was present in group III (Table 2), we used stepwise discriminant analysis to determine whether group I patients could be distinguished from those in group III on the basis of Candidates for entry included all hematologic and serum chemistry values and calculated globulin concentration and A/G ratio. I, patients with acute ischemic stroke; II, those with transient ischemic attack of brain; III, those with risk factors for stroke; IV, normal subjects; A/G, albumin concentration-to-globulin concentration. viscosity-related variables. As shown in Table 5 , the final model consisted of three laboratory measurements. Albumin and fibrinogen concentrations, both of which profoundly influence plasma viscosity and, by extension, whole-blood viscosity (see Tables 3 and  4) , were two of the key variables identified. Mean erythrocyte cell volume (MCV), the third variable in the model, also has a recognized cellular influence on the viscosity of whole blood. 12 With these three variables, Tukey's jackknife procedure correctly classified approximately 64% of the group I and 74% of the group III subjects.
Discussion
Our results are consistent with the hypothesis that chronic blood hyperviscosity antedates the onset of Candidates for entry were total protein, globulin, albumin, and fibrinogen concentrations; A/G ratio; hematocrit; mean erythrocyte hemoglobin concentration and cell volume; platelet and leukocyte counts; and plasma and whole-blood viscosity. I, patients with acute ischemic stroke; III, those with risk factors for stroke; A/G, albumin concentration-to-globulin concentration. symptomatic cerebrovascular disease. Whole-blood and plasma hyperviscosity, together with underlying abnormalities in blood protein profiles, were present in group III as well as in groups I and II. The increase in the severity of viscous abnormalities from group IV to group I indicates that the factors that contribute to blood hyperviscosity covary with the severity of illness. In all groups hematocrit, together with plasma viscosity, accounted for approximately 80% of the variability in whole-blood viscosity at low rates of shear. In turn, roughly 70% of the variation in plasma viscosity was dependent on the calculated concentration of globulin and the fibrinogen concentration. These data agree well with other models predicting whole-blood and plasma viscosity, including that reported by de Simone et al, 13 who measured viscosity and plasma protein concentrations in a population of apparently healthy adults. Significantly, the hematocrit, which is the single most important influence on whole-blood viscosity, did not differ appreciably among our study groups. Thus, group differences in whole-blood viscosity are traceable to the influence of altered blood proteins, particularly an elevated fibrinogen level, in conjunction with a decreased albumin concentration and A/G ratio. This pattern of abnormalities is most pronounced in group I subjects, particularly those with a history of stroke or TIA. Discriminant analysis provides further evidence that the degree of hyperviscosity is related to the severity of disease since we could distinguish group I from group III by a model that incorporated the viscosityrelated variables albumin concentration, fibrinogen concentration, and erythrocyte MCV. Since risk factors and medications were closely matched in groups I and III, it is unlikely that these factors were responsible for the difference in hyperviscosity between the two groups.
These observations are consistent with those of Ernst et a], 14 who observed abnormal plasma viscosity, cellular filterability, and erythrocyte aggregation both in subjects with acute TLA and in an asymptomatic group balanced for risk factors. Our results stress the importance of a control group balanced for risk factors as well as a control population free of recognized stroke risk factors since blood viscosity was clearly abnormal in groups I, II, and III compared with group IV.
Since the differences in whole-blood viscosity were most evident at lower rates of shear, it is likely that enhanced erythrocyte and possibly leukocyte aggregation due to higher fibrinogen and lower albumin levels are the most important contributors to wholeblood hyperviscosity in this population. Although the magnitude of shear forces in the vasculature usually prevents erythrocyte aggregation, aggregability may be pathogenetic in low-shear situations in which hypoperfusion prevails (e.g., when vascular compensation has reached its limit). 15 Furthermore, these viscosity factors may also be critical within the socalled watershed or "hemodynamic" arterial territories. A recent report 16 described significantly increased erythrocyte aggregability in patients with acute stroke but, perhaps more importantly, found the same pattern of hyperaggregability to be a persistent feature of chronic occlusive cerebrovascular disease. The same study found that erythrocyte aggregability in stroke patients was significantly correlated with circulating levels of fibrinogen and globulins and inversely correlated with the A/G ratio. Others have demonstrated an inverse relation between fibrinogen levels and cerebral blood flow. 17 Serum globulins, especially a 2 -macroglobulins and the immunoglobulins IgG and IgM, also exhibit a fibrinogen-like influence on blood viscosity that is more pronounced under low-flow conditions in which erythrocyte aggregation is favored. 18 Our results, like those obtained by Fisher and Meiselman, 19 underscore the notion that, in addition to elevated fibrinogen levels, other cellular and plasmatic factors may contribute to blood viscosity abnormalities. A recent review 20 has emphasized that further attention to the role of plasmatic factors in cerebral infarction is warranted.
The low A/G ratio in conjunction with an elevated fibrinogen level in groups I, II, and III suggest that chronic, subacute as well as acute-phase protein changes may underlie blood hyperviscosity. 21 The low A/G ratios seen in these three groups reflect both hypoalbuminemia and, to a lesser extent, an increased globulin fraction. A reduced serum albumin concentration in acute stroke patients is reported to reflect a poor nutritional status during the acute event.
22 - 24 However, in the absence of a significant decline in the total protein concentration, we hypothesize that altered hepatic synthesis or transvascular albumin loss are the key contributors to the reduced A/G ratio in these subjects. Supporting this view are results from a prospective study comparing the dietary habits of Japanese fanners and fishermen. Kimura and colleagues 25 - 26 found a strong relation between a reduced serum albumin concentration or A/G ratio and stroke occurrence that could not be explained solely by the nutritional status of the participants.
In this cross-sectional study, we cannot exclude the possibility of an acute-phase response following brain infarction. However, since the severity of the viscous abnormalities in group II were almost equal to those in group I, it is unlikely that a secondary acute-phase response is the principal explanation for elevated blood viscosity in patients with acute stroke. This conclusion is supported by other observations. Syrjanen and colleagues 27 measured acute-phase proteins £72 hours after acute stroke and found increases in only 11 (24%) of 46 subjects. These authors argued that an acute-phase response, when present, most often reflected a prestroke infection that may have promoted a prothrombotic state. Likewise, Sandset and Andersson 28 found only modest elevations in the concentration of C-reactive protein, an acute-phase reactant, after acute stroke. It appears, therefore, that the alterations in the albumin concentration, the A/G ratio, and the fibrinogen concentration that accompany acute stroke are not coupled to acutephase protein regulation, but rather to a "chronic"-phase activation. The chronic-phase protein response in our subjects is similar to the "hematological stress syndrome" described by Reizenstein, 29 although the concomitant changes in blood viscosity were not investigated in earlier studies. 30 Our results have several potentially important applications to both clinical and investigational approaches to subjects with cerebrovascular disease. The finding that a low A/G ratio correlates with blood hyperviscosity may prove to be a useful clinical index since this ratio is precise and widely available. Although elucidation of the mechanism(s) responsible for chronic hyperviscosity in stroke patients will require further examination in a properly designed longitudinal study, long-term treatment strategies that normalize blood flow properties may decrease the likelihood of stroke in subjects with recognized risk factors for stroke.
